Short-term effects of intravitreal bevacizumab in type ii idiopathic macular telangiectasia.
To report the effect of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia (type 2 IMT). Interventional case report. A 51 year-old female patient with type 2 IMT presented with gradual visual deterioration and reading difficulties. In one affected eye, two intravitreal bevacizumab injections were performed with a four weeks interval. Examinations included ETDRS visual acuity, slit-lamp biomicroscopy, digital fluorescein angiography, optical coherence tomography (OCT) and microperimetry at baseline and during a 12-week review period. Following treatment the patient noted a visual improvement particularly during reading. On angiography a reduction in size and intensity of the hyperfluorescent area was recorded and the retinal sensitivity improved on microperimetry. In absence of other efficacious therapeutic modalities, the observations indicate a beneficial therapeutic effect of intravitreal bevacizumab in type2-IMT, and implicate a pathophysiological role of VEGF in this disease entity.